Arati Desai, MD

Pai EL, Nazarian MN, Kenyon AL, Abdullaev Z, Arisi M, Johnson ES, Surrey LF, Quezado M, Schwartz LE, Dumoff KL, Cooper K, Aldape K, Kenyon L, Nasrallah MP, Desai AS. Longitudinal neuropathologic and molecular characterization of a retroperitoneal ependymoma , J Neuropathol Exp Neurol, 85: 2026,913-917

Linkowski L, Messing I, Berger M, Hollawell C, Friedes C, Alexander D, Wang X, Desai AS, Phillips RE, O'Rourke DM, Amankulor NM, Jackson C, Hubbeling H, Kurtz G, Bagley SJ, Bradley JD, Mohan S, Alonso-Basanta M, Lebow ES. Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series , Int J Radiat Oncol Biol Phys: 2026

Li EJ, Kraya A, Costa-Pinheiro P, Scheuermann J, Young AJ, Schubert E, Aboian M, Doot R, Ware JB, Pantel AR, Binder ZA, Storm PB, Resnick AC, Amankulor NM, O'Rourke DM, Desai A, Nasrallah MP, Brem S, Bagley SJ, Mankoff D, Nabavizadeh A. Metabolic Imaging and Molecular Signatures Reveal Metabolic Phenotypes in Recurrent Glioblastoma , J Nucl Med, 67: 2026,849-856

Ellingson BM, Cloughesy TF, Ye X, Teraishi A, Raymond C, Oshima S, Sanvito F, Wen PY, Walbert T, Campian JL, Nabors LB, Ozer BH, Desai A, Omuro A, Desideri S, Danda N, Grossman SA, Bindra RS, Schiff D. Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801) , AJNR Am J Neuroradiol: 2026

Zhou DJ, Jaskir M, Gal J, Fonkeu Y, Davatzikos C, Nasrallah MP, Garcia J, Xing R, Bagley SJ, Desai A, Phillips RE, Tobochnik S, Ellis CA, Gugger JJ, Sinha N, Stein JM, Davis KA. Spatial and Volumetric Characteristics of Glioblastoma: Associations With Clinical Presentation and Survival , Ann Clin Transl Neurol: 2026

Akbari H, Mohan S, Liu F, Jiang C, Fathi Kazerooni A, Berger M, Rathore S, Bilello M, Sako C, Garcia J, Brem S, Bakas S, Mamourian E, Pepin A, James P, Dorsey J, Singh A, Parker D, Verma R, Cao Q, Bagley SJ, Desai A, O'Rourke DM, Shinohara RT, Nasrallah MP, Teo BK, Kurtz G, Shukla G, Alonso-Basanta M, Lustig RA, Davatzikos C. Personalized machine learning-guided radiation dose escalation in newly diagnosed glioblastoma: prospective pilot study , Nat Commun, 17: 2026,6413

Cordell EC, Mansour M, Pantel AR, Schubert E, Nabavizadeh A, Mohan S, Maloney E, Prior T, Angeloni N, Blessing C, Frangos S, Coghlan L, Wileyto EP, O'Rourke DM, Brem S, Desai AS, Bagley SJ. A phase 2 study of niraparib concomitant with tumor treating fields in patients with recurrent grade 4 glioma , Neurooncol Adv, 8: 2026,vdag076

Friedes C, Berger M, Linkowski L, Hollawell C, Hubbeling H, Alexander D, Kurtz G, Lustig RA, Dorsey JF, Desai AS, Phillips RE, Brem S, Davatzikos C, Nasrallah M, O'Rourke DM, Jackson C, Amankulor NM, Alonso-Basanta M, Mohan S, Bagley SJ, Lebow ES. Clinical, molecular, and immunologic determinants of survival in WHO-defined IDH-wildtype glioblastoma treated with radiotherapy: a large real-world cohort study , J Neurooncol, 177: 2026,125

Schiff D, Ye X, Li J, Ellingson BM, Wen PY, Walbert T, Campian J, Nabors LB, Ozer BH, Desai A, Omuro A, Desideri S, Danda N, Grossman S, Bindra RS. Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas , Neuro Oncol, 28: 2026,485-494

Lim M, Ye X, Piotrowski AF, Desai A, Ahluwalia MS, Walbert T, Lesser G, Ellingson BM, Peereboom DM, Fisher JD, Desideri S, Jackson C, Pant A, Jain A, Verma R, Oberlton B, Piyadasa H, Bettegowda C, Engle L, Taube J, Bendall SC, Choi J, Drappatz J, Lieberman FS, Kleinberg LR, Pardoll DM, Nabors LB, Wen PY, Grossman SA. Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial , Nat Med: 2026